

OMNIVISTA

SEP - 2025





In this episode, Vikas Gupta, CEO of Omniscience Capital, explores capexdriven banking growth, emerging power-hungry sectors, global opportunities, and why liquidity and valuation outweigh brand names.

Watch here...

This document is released by OmniScience Insights Labs and it is independent of any registration-related activities of Omniscience Capital Advisors Private Limited. It does not constitute a "research report" under SEBI (Research Analyst) Regulations, 2014, or "investment advice" under SEBI (Investment Adviser) Regulations, 2013. It is also not a solicitation or offer under SEBI (Portfolio Managers) Regulations, 2020, which govern discretionary, non-discretionary, and advisory PMS services.

Investments in securities markets are subject to market risks. Read all related documents carefully before investing. SEBI registration, BSE membership, or NISM certification do not guarantee returns or the reliability of any intermediary. We, or our associates, may hold long or short positions in the securities of the companies mentioned in our reports/documents. Past performance is not indicative of future outcomes.

The content herein is intended solely for educational and knowledge-building purposes, designed to provoke thought and share insights.



SEPTEMBER MONTH OVERVIEW

GROWTH VECTOR: LOGISTICS + MFG

A key driver of India's logistics boom is rising industrial output, backed by Make in India and PLI schemes. As sectors like electronics, renewables, autos, and chemicals scale up, domestic capacity grows- fueling parallel demand for efficient, reliable logistics to support this expansion and supply chain competitiveness.

Read our full report here...



OMNIVIEW - SEP 2025

Only Scientific Investors can benefit from OmniScience's Scientific Investing Framework

Most clients of investment services choose their fund manager or adviser based on the past performance of the fund. Even here the focus is on the recent performance. Typically, they would choose the fund manager with the highest recent performance. Of course, what is recent performance itself varies by time frame from last 1 month, to last 1 year to very rarely last 3 years. Hardly anyone looks beyond that.



Dr. Vikas V. Gupta

While the real track record to evaluate is how a fund manager has performed over a full market and economic cycle. This would be at least a 5-year period with one bull and one bear market, at least. Similarly, the period should cover an economic boom and an economic recession period. The economic and market cycles can differ in timings of their ups and downs.

Now coming to what the clients believe when they are outsourcing to a fund manager. They have a view of how one should participate in the markets and benefit from them.

Some who have been exposed to trading think that they are outsourcing their trading to their fund manager. The reason to outsource is that the fund manager is more "professionally trained", so he will trade better. He is full-time employed in this, so will trade better. He has access to more resources, so he will trade better. He is being paid professionally for this, so he will trade better. The flaw is that because the client believes trading is the way to make money in the markets, he thinks the fund manager would do what the client does but at an amplified pace and size.

So they expect the fund manager to work with their concepts of trying to find stocks which will go up in the near term and then get out of them just before they peak and move into other stocks just in time to buy them before they start going up. Also, the fund manager should be able to sell at market peaks and move into cash and buy at market bottoms and deploy cash.



So their objective is a nearly monthly or 3-monthly (very long term in their opinion) profit making cycle. So deliver 5% per month, or some are more liberal, deliver even 5% per quarter, and they are happy. And don't let the portfolio become negative. Let it be positive with a 5% per quarter return and that is all they ask for. Is that too much to ask for? Especially when they are paying fund management fees?

We think that clients should understand that the reason they are outsourcing is to get it managed professionally by people who understand the nature of the economy and markets and understand how to define the objectives and processes of what fund management is about.

We have done that with the Scientific Investing Framework. The objective is not to generate 5% per quarter, but to generate returns higher than the markets (typically represented by Nifty 50, Nifty 500 or S&P 500 etc.) over the long-term while also attempting to preserve capital. Typically, this term could be 5 years or more, and most of the times it could happen within 3 years too. But the objective is not to chase short-term returns since that is likely to ensure poor performance over the long-term. Of course, the nature of the markets is such that no one can guarantee that the objectives are met.

The Scientific Investor, who is the ideal client for OmniScience's investment services, has the following characteristics: Originality, Character and Patience. He knows that to generate alpha the investment process has to be original and the portfolio has to be original, meaning the selection process is different from what most market participants are following and the resulting portfolio is different from the market portfolio.

Similarly, going against the market and allocating capital to an original portfolio requires strength of character. Since, money is being put into stocks which are not the favorites of Mr. Market, they are likely to perform negatively in the near term. This requires significant character strength and belief in the selection process and investment philosophy.

Finally, the portfolio is expected to work out over the 3-5 year timeframe. So it requires patience. In the near term, the portfolio could be volatile and look negative.

Why does the Scientific Investing Framework require such a Scientific Investor as client?

Scientific Investing focuses on buying companies with strong businesses generating profits and ideally positive cash flows. Further, these companies have large growth opportunities, being exposed to long-term growth vectors, and have capabilities and resources to capture and benefit from those growth vectors. Finally, these are companies which Mr. Market currently dislikes due to either ignorance about their opportunities or due to some near-term, temporary negative sentiments. This situation helps in making these great companies available at great prices, meaning they are available at significant discounts to their intrinsic values.

So the revenues, earnings, cash flows and networth of these companies are stable or growing but they are available below the valuations they should be at given their growth rates and capital efficiency. During the "holding period" or the "patience period", the stocks are likely to continue growing their fundamentals, i.e., revenues, earnings and networth. However, the valuation re-rating could take anywhere from 6 months to 6 years or more, though typically the observation is that it happens in 18 months to 36 months.

Due to the above dynamics, OmniScience's Scientific Investing Framework is suitable only for the Scientific Investors. We wish others the best!



Q1 GDP REPORT: INDIA ACCELERATES TOWARD ROBUST GROWTH

FY26 Q1 GDP growth rate signals a return to a high-growth economic regime. Over the last three quarters we see a clear uptrend (3Q25: 6.4%, 4Q25: 7.4% and now 1Q26: 7.8%). The Q1 growth was one of the fastest growths among major economies such as USA (2.1%), China (5.2%), Japan (1.2%), UK (1.2%) and France (0.7%). The first quarter growth is robust as strong growth is seen across sectors such as manufacturing (7.7%) and construction (7.6%) and services (9.3%).



Ashwini Kr. Shami

We expect this growth momentum to continue with support from the current festive season and the consumption boost due to tax cuts and a benign interest rate environment. Some of the leading indicators such as PMI data suggest the same. Services PMI surged to 62.9 in August 2025 - the fastest pace seen in the last 15 years. Manufacturing also surged, lifting the composite PMI to a 17-year high of 63.2.

The government's long-term strategic investments in infrastructure coupled with policy reforms is showing in a low and stable inflation environment with easing of supply chain bottlenecks. The recent CPI numbers have ranged between 1.6% to 2.1% over the past three months and the inflation projection for FY26 is around 3%. The July inflation rate at 1.61% was the lowest reading since Jun 2017. Additionally, negative food inflation was observed in Aug 25, down from 10.9% in Oct 2024. While a low and stable inflation rate environment boost consumption, it may also be noted that all these current and projected inflation numbers are at the lower end of the RBI's target range of 2-6% and hence there is a strong case for further rate cuts by the central bank. Fiscal measures announced by the government to support growth along with the expected policy rate cuts from 50-100bps by the end of this financial year could spur consumption further and provide continued support for economic and earnings growth.

On the international front, we see the US-tariff related trade tensions to have limited impact on the GDP growth as progress can already be seen toward a trade agreement. Trade negotiations process is anyway expected to involve multiple stages, and the first tranche of the trade deal could be expected around November. Meanwhile, India has either concluded or is currently negotiating trade deals with several countries, including the UK, EFTA, UAE, Mauritius, and Australia, which gives it additional leverage in bilateral discussions with the U.S. while opening new avenues for growth of exports.

In the near term we expect U.S. Fed to cut policy rates and switch to an accommodative stance to focus on stimulating economic growth amid slowing labour market, provided the inflation numbers remain relatively stable. This could be a significant trigger for FII inflows, potentially driving markets higher. We have seen continuously strong DII net buying, and any pause in FII net selling- similar to the trend seen from March to June this year- is expected to be a positive catalyst for the markets.



MACROECONOMIC INDICATORS

ECONOMIC ACTIVITY:

Macro Trends	Current	Previous	Latest Reported Date
S&P Global Manufacturing PMI	59.3	59.1	Sep 01, 2025
India Nikkei Services PMI	62.9	60.5	Sep 03, 2025
Bank loan growth(%)	10.2%	9.8%	Aug 29, 2025
Deposit growth (%)	10.1%	10.1%	Aug 29, 2025
India Industrial Production YoY	3.5%	1.5%	Aug 28, 2025 (Jul)
Trade Balance (E-I) (Billion USD)	-27	-19	Aug 14, 2025 (Jul)
Monetary:			
WPI (YoY)	-0.58%	-0.13%	Aug 14, 2025 (Jul)
CPI (YoY)	1.55%	2.10%	Aug 12, 2025 (Jul)
Repo Rate	5.50%	6.00%	Jun 06, 2025
Bank Rate	5.75%	6.25%	Jun 06, 2025

GDP:

Particulars	Q4FY25 (Est.)	FY25 (Est.)	Q1FY26 (Est.)	FY26 (Est.)
Nominal GDP growth (%)	10.8%	9.8%	8.8%	10.1%
Real GDP growth (%)	7.4%	6.5%	7.8%	6.7%

OTHER KEY INDICATORS:

Particulars	Aug 31, 2025	Jul 31, 2025	Change
India 10-yr Bond Yield	6.59%	6.38%	+21 bps
USD/INR	88.2	87.5	-0.74%
FX Reserves (Billion USD)	691	698	-1.07%
FII Net Buy/-Sell (Rs Cr)	-46,903	-47,667	-72,572 (YTD)
DII Net Buy/-Sell (Rs Cr)	94,829	60,939	3,24,312 (YTD)
Commodities:			
10g Gold	1,06,400	1,01,260	5.1%
1 Kg Silver	1,25,000	1,13,000	10.6%
Crude Oil (USD/Bbl)	64	69	-7.6%
Lithium (CNY/T)	79,740	72,045	10.7%
Cobalt (USD/T)	33,335	33,335	0.0%

Particulars	Month	2025	2024	Δy-o-y (%)
GST Collection (Rs Cr)	Aug	1,86,315	1,74,962	6.5%
UPI Transactions Value (Rs trillion)	Aug	24.9	20.6	20.6%
No of UPI Transactions (Volume in Cr)	Aug	2,001	1,496	33.7%
Power Generation (BUs)	Aug	134	131	1.9%

Source: OmniScience Insights Labs, https://in.investing.com/economic-calendar/, https://www.npci.org.in/what-we-do/upi/product-statistics, https://tradingeconomics.com



OmniScience Smallcases: Valuation Metrics as of 31st Aug 2025

Product Name	P/E	P/BV	Div. Yield
Omni Super Dividend	7.9	1.2	3.63%
Omni Capital Enablers	8.5	1.1	2.03%
Omni Bank on Bharat	8.8	1.1	1.81%
Omni Knights - MidCap	9.7	1.2	2.00%
Omni Royals - LargeCap	11.3	1.6	2.04%
Omni Flexicap Superstox	11.4	1.4	1.87%
Omni Commercial Czars	11.5	1.5	2.37%
Omni UP & Ayodhya	12.3	1.5	1.83%
Omni Power - Electrifying India	12.3	1.6	2.16%
Omni Fintech, Digital Bank & Payments	12.4	1.6	1.57%
Omni Amrit Kaal	12.8	1.6	1.63%
Omni Supertrons - Smallcap	15.5	1.9	1.22%
Omni Future of Mobility	17.3	2.2	1.57%
Omni Bharat Defence	20.9	2.7	1.32%
Omni DX- Digital Transformation	20.9	3.5	1.83%
Omni Bullet Train	21.0	2.7	1.49%
Omni Al-Tech Global	21.7	3.7	1.87%
Omni Manufacturing Magnates	22.7	3.0	0.98%
Benchmarks	-	-	
Equity Largecap	22.6	3.5	1.32%
Equity Midcap	33.8	4.7	0.88%
Equity Smallcap	43.3	5.5	0.47%
Equity Multicap	26.1	3.9	1.12%

Source: OmniScience Insights Labs, https://omniscience.smallcase.com



Equities Market: Performance as of 31st Aug 2025

Total Returns (%)	1 Month	1 Yr	5 Yr
Nifty 50	-1.2%	-2.0%	17.9%
Nifty Midcap 150	-2.8%	-4.8%	27.6%
Nifty Smallcap 250	-3.6%	-8.6%	28.8%

Equities Market: Valuation Metrics as of 31st Aug 2025

Sectoral Indices	P/E	P/B	Div. Yield
Nifty PSU Bank	7.0	1.1	2.8%
Nifty Oil & Gas	11.4	1.5	2.4%
Nifty Bank	14.6	2.0	1.1%
Nifty Financial Services	16.7	2.7	1.1%
Nifty Private Bank	17.5	2.0	0.6%
Nifty Metal	17.5	2.4	2.5%
Nifty 50	21.5	3.3	1.4%
Nifty 500	23.5	3.5	1.2%
Nifty IT	25.4	6.8	3.1%
Nifty Auto	25.6	4.5	1.2%
Nifty Smallcap 250	31.5	3.6	0.7%
Nifty Pharma	31.6	4.7	0.7%
Nifty Midcap 150	32.1	4.5	0.9%
Nifty Healthcare Index	37.2	5.4	0.6%
Nifty Realty	41.8	4.1	0.3%
Nifty FMCG	42.1	10.7	2.0%
Nifty Consumer Durables	69.5	13.6	0.4%



India's Manufacturing Revolution: Investing in the Next Phase of Amrit Kaal

The Indian manufacturing sector currently stands as one of the primary growth sectors in India, catering to both domestic and international markets. First 2 phases of India's transformation through the Amrit Kaal vision focused on building the digital and the physical infrastructure.

India is poised to continue emerging as a preferred destination for manufacturing investments due to the availability of raw materials, low labor costs, a favorable corporate tax rate for manufacturing, and proactive government support through incentives.

The Industry sector currently accounts for 27.3% of India's GDP, and is expected to increase its share to more than 30% by 2035. By then India's GDP will potentially reach \$10 trillion, giving more than \$3 trillion opportunity for Industry sector as compared to \$1 trillion now.

The manufacturing sector's expansion will not only contribute to GDP growth but also generate substantial employment, reduce import dependency, and improve trade balances. To realize this potential, the sector must adopt advanced manufacturing technologies, improve supply chain efficiencies through infrastructure development, and foster a conducive business environment.

Inside the report:

- The state of Indian Manufacturing
- Global Economic Landscape
- Key Growth Drivers
- Impact of PLI Schemes
- o Case Study: Atmanirbhar Bharat in Defence
- Valuation Insights



Download Report...



Scientific Investing & Global Opportunities | Omniscience Capital | Vikas Gupta

In this episode of MPU – Market Pillars Uncovered, meet Vikas Gupta — CEO at Omniscience Capital and a pioneer of scientific investing. From identifying industries to watch, to decoding opportunities across Indian and global markets, he dives deep into capex-driven banking growth, the power-hungry sectors of the future, and why liquidity and valuation matter more than just a great company name.

- What you'll hear in this episode:
 - Industries to Watch Out For
 - How to Invest in Indian and Global Markets
 - Insights into Scientific Investing
 - Focus on Cap Size
 - Deep Dive into Global Investment Opportunities

Watch full episode here...



Scientific Investing & Global
Opportunities | Omniscience Capit...



OmniScience in the NEWS

1 Want Rs 3 Cr By 60? Here's The Right 12-Year SIP Strategy for A 48-Year-Old Earning Rs 4 Lakh

A 48-year-old earning Rs 4 lakh/month can realistically build a Rs 3 crore corpus by 60 through disciplined SIPs of Rs 1–1.3 lakh/month, assuming 10–12% returns. Experts caution, however, that Rs 3 crore is too modest- Rs 10–15 crore is a more suitable goal given rising costs and longevity.





2 Manufacturing Growth

India, now the world's 4th-largest economy, struggles with manufacturing—only 14% of GDP in FY25 versus China's 26%—while services dominate at 55%. Despite weak merchandise exports (1.8% global share), policies like PLI and Make in India are boosting sectors like electronics, pharma, and engineering, hinting at a \$3T industrial opportunity by 2035.







3 Quote on Monthly Market Commentary by Ashwini Shami, President and Chief Portfolio Manager at OmniScience Capital

July saw a broad market correction, with Nifty 50, midcap, and smallcap indices down 2.8–3.6%, FII net selling of ₹47k cr, but DIIs supported with ₹60k cr inflows; IT, Defence, Media, and Realty lagged amid valuation concerns.





4 Donald Trump looks to ramp up tariffs on semiconductors. Will it impact the Indian auto sector?

The proposed 25% U.S. tariff on semiconductors could disrupt global supply chains, impacting industries reliant on chips, including India's automotive sector.





5 Tariff turmoil prompts rethink: Investors pivot to domestic plays amid global trade shock

Global tariff uncertainties are pushing investors to pivot from export-heavy sectors to domestic demand-driven plays like banking, FMCG, and infrastructure.







6 Quote on RBI MPC Announcement by Dr. Vikas Gupta, CEO & Chief Investment Strategist at Omniscience Capital

Dr. Vikas Gupta noted that with inflation at target and GDP growth steady, the RBI's neutral stance is prudent, though US tariffs on Indian exports could add market volatility.





7 Want expert to decide fund picks, allocation, rebalancing? Go for FoF

Fund-of-Funds provide diversified, expert-managed investment across multiple mutual funds, simplifying allocation and rebalancing, but come with higher fees and tax complexities.

Business Standard



8 China outpaces India amid emerging market turmoil; valuation gap hits record \$6.3 trillion

India's equity market lags China, with MSCI India up 2.2% vs. China's 9.4% over three months, creating a record \$6.3 trillion valuation gap as India trades at 21× forward earnings versus China's 11.9×.





China outpaces India amid emerging market turmoil; valuation gap hits record \$6.3 trillion

According to data from Bloomberg, the MSCI India Index has lagged its Chinese counterpart by nearly 10 percentage points this quarter, marking India's worst relative annual performance since 2017. Currently, the MSCI India trades at more than 21 times its one-year forward earnings, compared to just 11.9 times for China.



Stock Market Outlook: Sensex, Nifty Recovery Signals Bullish Intent Amid DII Buying; Key Resistance at 25,000

Commenting on the potential impact of the U.S. tariff hike, Vikas Gupta, CEO of Omniscience Capital, noted that while the move could affect approximately \$48 billion or 55% of Indian exports to the U.S., the overall impact on the broader Indian market may be limited.





MFs inflows up 81% to ₹42,702 cr in July

Vikas Gupta, CEO of OmniScience Capital, said that the investors seem to be following a policy of buy more on dips and continue with the sips.



MFs inflows up 81% to ₹42,702 cr in July

RAVI RANJAN PRASAD MUMBAI, AUG. 11

MUMBAI, AUG. 11

The equity mutual fund (MF) inflows rose sharply by 81.04 per cent to record ₹42,702.35 crore in July as investors took advantage of market correction. compared to ₹23,587.05 crore in June, according to the Association of Mutual Funds in India(AMFI).

Monthly inflows through systematic investment plan (SIP) also rose to a new high of ₹28,464 crore while MF industry's total assets under management (AUM) rose to new high of

MONTHLY inflows through SIPs in July rises to a new high of ₹28,464 crore.

DEBT MF inflows stood at over ₹1,068 lakh cr as compared to out-flow of ₹1,711.4 lakh crore in June.

STOCK markets recovered on Monday from Friday's loss with bechark index Sensex gaining 746.29 pts.

Despite steep tariffs, OmniScience's Vikas Gupta sees strong earnings recovery in 2HFY26

Despite the hefty tariff rate of 50 percent, Vikas Gupta, the CEO and Chief Investment Strategist at OmniScience Capital, still anticipates a strong earnings recovery in the second half of FY26. "The tariffs shouldn't have too much impact on the earnings of most sectors," he said



Daily Voice: Despite steep tariffs, OmniScience's Vikas Gupta sees strong earnings recovery in **2HFY26**

It is quite likely that a year from now the tariffs should be much lower, said Vikas Gupta of OmniScience Capital. Join Us
 Follow Us
 Add as a preferred source on Goodle - SUNIL SHANKAR MATKAR | AUGUST 13, 2025 / 06:50 IST



12 Are asset managers a safer bet than brokers in India's capital market?

According to a report by Omniscience Capital, India's manufacturing sector is expected to play a pivotal role in driving economic growth, contributing 20% to the country's GDP by 2035 and presenting a potential market opportunity worth USD 3 trillion.





SBI Subsidiaries: ₹3.5 Trillion 'Hidden' Gems


Stripping out overvaluation and applying a holding company discount, we estimate a realisable value of around 2.5 trillion," OmniScience Capital said in a recent note.



The development follows a irective from the finance ninistry to public sector unertakings to list their subsidiertakings to list their subsidi-ries as part of a wider gov-rnment strategy of improving eturns on state-owned assets, nlocking value, and enhanc-ng governance standards.

Najor subsidiaries

If the five main subsidiaries, BI Life (the industry leader mong private players), and BI Life (the industry leader mong private players), and BI Cards (the arm that han-les the bank's credit card usiness wherein it is the send largest with a tad over 20 aillion customers) are already isted with a market cap of ₹ .84 lakh crore and ₹62,035 rore, respectively as of Australia (TSB moves ahead rith IPOs, starting with SBI dutual Fund, it could mark a aluation inflection point,



Bank (₹15.3 lakh crore) and Bank (*15.3 lakh crore) and ICICI Bank (*10.2 lakh crore). With the two listed arms, SBI group already commands a meap of *10.1 lakh crore. Analysts believe that SBI's powerful but under-appreciated and hidden value of its sub-

value-based on market cap and value-based on market cap and AUM benchmarks. Stripping out overvaluation and applying a holding company discount, we estimate a realisable value of around ₹2.5 trillion," OmniScience Capital said in a recent note.

and SBI Global Factors which ave contributed over \$1,00 crore in aggregate profit. The FY25 annual report pegs the trail pre-tax profit of subsidiaries and associates at 714,21 crore, with SBI Life accounting for nearly a third of that.

"We continue to value theore bank at 1.2x FY27 adjusted book value, with subsidiaries contributing 7241 per shar to our target price of ₹960," as cording to a recent note by Jb Financial. Motifal Oswal peg the value of SBI's subsidiarie even higher at ₹245 per shar and sees them as the key rating triggers. "We maintai SBI as our top buy amon state-run banks with a targe price of ₹925, premised on 1.2 FY27 adjusted book value plu ₹245 for subsidiaries, "the brk kerage said. Nirmal Bang goe a step further valuing the sut

Bulls back in action on Dalal Street! Why did Indian stocks rally today?

"GST reforms and rating upgrade indicate the strength of the Indian economy, fiscal stability and continued growth potential," pointed Ashwini Shami, chief portfolio manager at Omniscience Capital.







Bulls back in action on Dalal Street! Why did Indian stocks rally today?



Markets saw a significant surge, with the Sensex closing up 0.8 per cent and the Nifty 50 up 1



15 Trump tariffs on India in effect: Which countries stand to gain from India's pain? Explained

Ashwini Shami – President and Chief Portfolio Manager, Omniscience Capital, said that he sees significantly more headwinds for the US economy than the <u>Indian economy</u>, as 30-35% tariffs are imposed on Canada, Mexico and China, the largest exporters to the US, accounting for more than \$1.3 trillion of imports.





16 Nifty extends its losing streak into August. Will GST talks, upbeat GDP, and Modi's China visit break the slide?

GDP growth of 7.8% for the first quarter of FY26 is encouraging and reconfirms the resilience of the Indian economy in the face of ongoing tariff turmoil and regional wars," said Ashwini Shami, president and chief portfolio manager at OmniScience Capital.





Nifty extends its losing streak into August. Will GST talks, upbeat GDP, and Modi's China visit break the slide?



Contact Us:

Omniscience Investment Adviser, Division of Omniscience Capital Advisors Pvt. Ltd.

info@omnisciencecapital.com | www.omnisciencecapital.com

Address: Awfis | 1st Floor | B Wing | Parinee Crescenzo | G-Block | BKC | Mumbai - 400051 Ph.: +91 90045 60540

Disclosures & Disclaimers

Omniscience Investment Adviser is the advisory division of Omniscience Capital Advisors Pvt. Ltd. which is registered as a non-individual Investment Adviser with SEBI with a valid registration No. INA000007623, BSE Enlistment No. 1197 and CIN U93000MH2017PTC290053. Principal Officer is Vikas V Gupta (Contact No. 9987681967,

Email: vikas.gupta@omnisciencecapital.com) and Compliance Officer is Chanchal Manglunia (Contact No. 9320816319, Email: chanchal.manglunia@omnisciencecapital.com). Local office address of Securities and Exchange Board of India is SEBI Bhavan, C4-A, G Block, BKC, Mumbai - 400 051.

Omniscience Research is the research analyst division of Omniscience Capital Advisors Pvt. Ltd. which is registered as a non-individual Research Analyst with SEBI with a valid registration No. INH000020077, BSE Enlistment No. 6517 and CIN U93000MH2017PTC290053. Principal Officer is Varun Sood (Contact No. 8879055519, Email: varun.sood@omnisciencecapital.com) and Compliance Officer is Chanchal Manglunia (Contact No. 9320816319, Email: chanchal.manglunia@omnisciencecapital.com). Local office address of Securities and Exchange Board of India is SEBI Bhavan, C4-A, G Block, BKC, Mumbai - 400 051.

Disclaimer:

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Any securities quoted above are for illustration only and are not recommendatory unless specified as advice. Nothing in this communication should be considered as implying any assured returns, or minimum returns or target return or percentage accuracy or service provision till achievement of target returns or any other nomenclature that gives the impression to the client that the investment advice/recommendation of research report is risk-free and/or not susceptible to market risks and/or that it can generate returns with any level of assurance. An investor should consider the investment objectives, risks, and charges & expenses carefully before taking any investment decision. Wherever there is the potential for profit there is also the possibility of loss. Therefore, investors may lose capital in markets. Past performance is not necessarily indicative of future results. This is not an offer document. This material is intended for educational purposes only and is not an offer to sell any services or products or a solicitation to buy any securities mentioned or otherwise. Any representation to the contrary is not permitted. This document does not constitute an offer of services in jurisdictions where the company does not have the necessary licenses. As a firm-wide philosophy and rule OmniScience Investment Adviser and OmniScience Capital Advisors Pvt. Ltd., or any of its employees, officers, management, directors, shareholders, associates, distribution partners or others related to the company in any other capacity, or any communication from the company, including any of its tagline, motto, slogan, etc. do not provide any guarantees on investment strategies or their returns etc. If you feel that you had been provided such guarantees at any time before or after the initiation of your relationship as an advisory client of OmniScience Investment Adviser, or, if any communication from OmniScience seems to give you a feeling that - "any investment advice implies any kind of assured returns or minimum returns or target return or percentage accuracy or service provision till achievement of target returns or any other nomenclature that gives the impression to the client that the investment advice is risk-free and/or not susceptible to market risks and or that it can generate returns with any level of assurance", then you agree to bring it to our notice immediately and initiate to terminate the advisory agreement with OmniScience. Individual returns of Clients for a particular portfolio may vary significantly from the performance of the other. No claims may be made or entertained for any variances between the performance depictions and individual portfolio



performance. Neither the investment adviser nor its Directors or Employees shall be in any way liable for any variations noticed in the returns of individual portfolios. Our discussion may include some information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual outcomes to differ materially. We assume no obligation to revise or publicly release any revision to these forward-looking statements in light of new information or future events. No guarantee can be given about the accuracy and/or completeness of the data, Omniscience makes no warranties or representations, express or implied, on the products and services offered. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or services. The information relating to any company or economic trends herein is derived from publicly available sources and no representation as to the accuracy or completeness of such information can be made. We may have recommended stocks, or stocks in the mentioned sectors to clients, including having personal exposure. This communication is confidential and is intended solely for the addressee. This document and any communication within it are void 30-days from the date of this presentation. It is not to be forwarded to any other person or copied without the permission of the sender. Please notify the sender in the event you have received this communication in error.

This document is released by OmniScience Insights Labs and it is independent of any registration-related activities of Omniscience Capital Advisors Private Limited. It does not constitute a "research report" under SEBI (Research Analyst) Regulations, 2014, or "investment advice" under SEBI (Investment Adviser) Regulations, 2013. It is also not a solicitation or offer under SEBI (Portfolio Managers) Regulations, 2020, which govern discretionary, non-discretionary, and advisory PMS services.